July 30, 2024 — A research group has developed a new method that further improves the existing CRISPR/Cas technologies: it allows a more precise and seamless introduction of tags into proteins ...

Labroots invites you to the 7th Annual Event in the CRISPR Virtual Event Series 2024 taking place on October 23rd, 2024! This event will continue the conversation of the abilities of CRISPR-based ...

Could advances in CRISPR technology be the solution? In the last decade, a new immunotherapy tool has entered the clinic. T cells engineered to express chimeric antigen receptors, known as CAR T ...

CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...

CRISPR is a technology that can be used to edit genes and, as such, will likely change the world. The essence of CRISPR is simple: it’s a way of finding a specific bit of DNA inside a cell.

CRISPR Therapeutics recently proved it was capable of getting a drug approved. Next, its oncology and cardiovascular disease programs will need to show value. It may soon face some financial ...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform.

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene editing tools to disable a gene mutation often seen in aggressive forms ...

And these immensely important novel biotechnologies may be on the cusp of a boom. That is in part because CRISPR-Cas9, the genetic engineering technology pioneered in 2012 to great fanfare (and a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other most promising gene editing stocks to buy according to hedge funds. The ...